On August 26, 2026, Alto Neuroscience promoted Nicholas C. Smith from Chief Financial Officer and Chief Business Officer to President and Chief Financial Officer. Consequently, CEO Amit Etkin relinquished the title of President but remains Chief Executive Officer. The company entered into a promotion and retention agreement with Mr. Smith providing for a $6 million cash retention payment: $3 million payable within ten days and $3 million on the twelve-month anniversary. These payments are subject to recoupment if employment terminates before the two-year mark, except in cases of death, disability, or termination without cause.

Alto Neuroscience, Inc. entered into an underwriting agreement on July 13, 2026, to conduct a registered direct offering of 3,776,436 shares of common stock at $26.48 per share. The company expects net proceeds of approximately $93.9 million to fund the clinical development of ALTO-207, specifically an additional Phase 3 trial for treatment-resistant depression, and for general working capital. The offering is expected to close on July 14, 2026. Alto Neuroscience, Inc. is a biotechnology company focused on developing neuroscience-based therapeutics.

Alto Neuroscience, Inc. announced that its estimated cash, cash equivalents, and restricted cash totaled approximately $244.2 million as of June 30, 2026. The company also announced plans to accelerate and expand the clinical development of its ALTO-207 program, which includes conducting an additional Phase 3 trial for treating treatment-resistant depression. Alto Neuroscience, Inc. is a biotechnology company focused on neurological disorders.